<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Techniques to reduce blood loss during abdominal or laparoscopic myomectomy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Techniques to reduce blood loss during abdominal or laparoscopic myomectomy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Techniques to reduce blood loss during abdominal or laparoscopic myomectomy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William H Parker, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Howard T Sharp, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tommaso Falcone, MD, FRCSC, FACOG</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1389281"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Uterine leiomyomas (myomas or fibroids) are smooth muscle tumors and are the most common type of pelvic tumors in women. Myomectomy is removal of the myomas, while leaving the uterus in place.</p><p>Myomatous uteri have an increased number of arterioles and venules and myomectomy may involve significant blood loss [<a href="#rid1">1</a>]. However, studies show that the blood loss is no greater than for hysterectomy, when controlled for uterine size [<a href="#rid2">2</a>]. The average volume of blood loss during abdominal myomectomy (performed via laparotomy, also referred to as open myomectomy) is 200 to 800 mL [<a href="#rid2">2-4</a>] and for laparoscopic myomectomy is 80 to 250 mL [<a href="#rid5">5,6</a>]. Surgical hemorrhage may result in anemia, hypovolemia, and coagulation abnormalities.</p><p>Bleeding can be prevented or decreased with mechanical or pharmacologic methods. Allogeneic blood transfusion can be avoided by using methods of autologous blood transfusion (autologous blood donation, intraoperative and postoperative blood salvage, or acute normovolemic [isovolemic] hemodilution).</p><p>Techniques to reduce blood loss during abdominal or laparoscopic myomectomy are reviewed here. Preoperative and postoperative care and surgical technique for abdominal or laparoscopic myomectomy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14195.html" rel="external">"Uterine fibroids (leiomyomas): Open abdominal myomectomy procedure"</a> and  <a class="medical medical_review" href="/z/d/html/15780.html" rel="external">"Uterine fibroids (leiomyomas): Laparoscopic myomectomy and other laparoscopic treatments"</a>.)</p><p class="headingAnchor" id="H3731788"><span class="h1">VASCULAR ANATOMY OF THE UTERUS AND LEIOMYOMAS</span><span class="headingEndMark"> — </span>The ascending blood supply of the uterus is from the uterine arteries, which pass through the cardinal ligament at level of the cervicouterine junction. The descending blood supply is from the ovarian arteries, which pass through the infundibulopelvic ligaments (suspensory ligaments of the ovary) and perfuse the ovaries, fallopian tubes, and uterine cornua  (<a class="graphic graphic_figure graphicRef54737" href="/z/d/graphic/54737.html" rel="external">figure 1</a>). The uterine and ovarian vessels anastomose to perfuse the uterus. Arcuate arteries run transversely within the uterine wall and radial arteries penetrate deeply into the myometrium [<a href="#rid7">7</a>].</p><p>The presence of leiomyomas in the uterus distorts normal vascular architecture [<a href="#rid8">8</a>]. Thus, the arcuate arteries may run in any axis, rather than transversely. Thus, either vertical or transverse incisions during myomectomy may transect these vessels. (See  <a class="medical medical_review" href="/z/d/html/14195.html" rel="external">"Uterine fibroids (leiomyomas): Open abdominal myomectomy procedure", section on 'Uterine incision'</a>.)</p><p>It has been the common teaching that there is a vascular pedicle at the base of each myoma and that ligation of this pedicle will achieve hemostasis during myomectomy. However, a study using vascular corrosion casting and electron microscopy revealed that myomas are surrounded completely by a dense, vascular layer supplying the myoma, which is separated from the myometrium by a narrow avascular cleft [<a href="#rid9">9</a>]. The key to reducing blood loss is to stay underneath this pseudocapsule when enucleating a fibroid.</p><p class="headingAnchor" id="H1389273"><span class="h1">PREOPERATIVE MEASURES</span><span class="headingEndMark"> — </span>Several preoperative measures can be taken to reduce the likelihood of postoperative anemia.</p><p class="headingAnchor" id="H1389432"><span class="h2">Correction of anemia</span><span class="headingEndMark"> — </span>Iron deficiency anemia associated with menorrhagia or dietary deficiency is the most common cause of anemia in the gynecologic patient population. In patients with abnormal uterine bleeding, a common symptom of uterine leiomyomas, laboratory testing for anemia should be part of the diagnostic evaluation. (See  <a class="medical medical_review" href="/z/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management"</a>.)</p><p>Preoperative anemia increases likelihood of blood transfusion and also increases the risk of perioperative morbidity and mortality. A systematic review of 20 observational studies confirmed the association between preoperative anemia and blood transfusion [<a href="#rid10">10</a>]. No meta-analysis was performed to quantify the magnitude of this effect, but in one representative study of 212 patients who underwent colorectal surgery, the rate of transfusion was significantly higher in those with a hemoglobin ≤12.5 g/dL compared with &gt;12 g/dL (49 versus 19 percent) [<a href="#rid11">11</a>]. The effect of preoperative anemia on perioperative morbidity was illustrated in a retrospective study of 1958 patients who underwent noncardiac surgery and declined blood transfusion for religious reasons [<a href="#rid12">12</a>]. A preoperative hemoglobin of ≤10 g/dL was associated with a threefold or higher increase in serious perioperative morbidity (cardiac events, respiratory failure, or serious bacterial infection) or mortality. </p><p>Preoperative anemia may be treated with iron supplementation. In surgical patients, intravenous iron alone increased hemoglobin levels by 1 to 2 g in as little as one week, and a review of 14 studies reported a clinically and statistically significant increase in hemoglobin in patients treated with intravenous iron alone [<a href="#rid13">13,14</a>]. Oral option is a good option in nonurgent cases. Strategies to correct anemia preoperatively are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3302.html" rel="external">"Management of hemorrhage in gynecologic surgery", section on 'Correction of anemia'</a>.)</p><p class="headingAnchor" id="H1389439"><span class="h2">GnRH agonists</span><span class="headingEndMark"> — </span>Preoperative use of gonadotropin-releasing hormone (GnRH) agonists provides some short-term benefits for patients undergoing myomectomy regarding blood loss and uterine size but may increase the difficulty of surgery [<a href="#rid15">15</a>]. In the long-term, their use appears to increase the risk of persistent/recurrent myomas.</p><p>Preoperatively, GnRH agonists can help correct anemia by temporarily inducing amenorrhea [<a href="#rid16">16,17</a>]. However, the clinical impact of these agents is controversial. A meta-analysis of 11 randomized trials compared patients planning abdominal myomectomy who were treated with a GnRH agonist for three to four months with those receiving either placebo or no treatment [<a href="#rid15">15</a>]. Preoperative GnRH agonist therapy resulted in a small, but statistically significant, increase in preoperative hemoglobin (1.0 g/dL higher). A further benefit of treatment with these agents was a reduction in intraoperative blood loss (68 mL less). Ultimately, however, there was no significant decrease in the risk of blood transfusion in patients treated with GnRH (14 percent for both treatment groups, odds ratio [OR] 0.86, 95% CI 0.26-2.85). This analysis was limited by insufficient statistical power to detect this difference.</p><p>Another potential benefit of GnRH agonists is reduction in uterine size. This may permit the use of a transverse rather than vertical laparotomy incision or may make a laparoscopic approach possible. (See  <a class="medical medical_review" href="/z/d/html/14195.html" rel="external">"Uterine fibroids (leiomyomas): Open abdominal myomectomy procedure", section on 'Role of GnRH agonists'</a> and  <a class="medical medical_review" href="/z/d/html/15780.html" rel="external">"Uterine fibroids (leiomyomas): Laparoscopic myomectomy and other laparoscopic treatments", section on 'Indication and alternatives'</a>.)</p><p>There are several important disadvantages of preoperative use of GnRH agonists. These agents make enucleation of fibroids more difficult by obscuring the tissue plane between the myoma and the myometrium [<a href="#rid18">18</a>]. Operative difficulty associated with GnRH agonist pretreatment has been measured in only one randomized trial, which found no difference in difficulty between pretreatment with a <a class="drug drug_general" data-topicid="10018" href="/z/d/drug information/10018.html" rel="external">triptorelin</a> compared with immediate surgery [<a href="#rid19">19</a>]. In our experience, however, operative difficulty <strong>is</strong> noticeably increased after pretreatment with these medications.</p><p>There is concern that pretreatment with GnRH agonists may increase the risk of persistent myomas because small myomas would shrink in size and would not be palpable during myomectomy. The meta-analysis described above reported a higher rate of postmyomectomy myomas in patients treated with GnRH agonists (11 of 17 patients [65 percent]) compared with placebo or no treatment (7 of 25 patients [28 percent]; OR 4.0, 95% CI 1.1-14.7) [<a href="#rid15">15</a>]. The sample sizes and number of events in this analysis were small, and the follow-up period ranged widely from 6 to 38 months. A subsequent randomized trial (n = 108) that compared eight weeks of <a class="drug drug_general" data-topicid="10018" href="/z/d/drug information/10018.html" rel="external">triptorelin</a> therapy with no treatment had a similar finding (proportion of patients with myomas at six-month follow-up: 8 versus 2 percent) [<a href="#rid19">19</a>].</p><p>Most of the data regarding GnRH agonists and myomectomy are for open procedures. The only randomized trial to address this issue in patients undergoing laparoscopic myomectomy found that GnRH agonist treatment compared with no treatment resulted in a significant increase in operative duration (45 minutes longer) and no decrease in blood loss [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/15780.html" rel="external">"Uterine fibroids (leiomyomas): Laparoscopic myomectomy and other laparoscopic treatments", section on 'Conversion to laparotomy'</a>.) </p><p>GnRH antagonists are another type of agent that suppresses endogenous GnRH. Their effects are similar to those of GnRH agonists, with the exception that results would be seen sooner, since GnRH is immediately suppressed. However, these agents are not widely used for a preoperative indication, since they are more expensive than GnRH agonists and require a daily injection. There are no high-quality data regarding use of GnRH antagonists prior to myomectomy.</p><p>Treatment with either GnRH agonists or antagonists is accompanied by menopausal symptoms (eg, hot flashes, mood disturbance) that many patients find difficult to tolerate.</p><p>In summary, there is no evidence that use of GnRH agonists prior to myomectomy reduces the risk of blood transfusion and such use may increase operative difficulty and the risk of myoma persistence/recurrence. The primary advantage of use of these agents is the ability to use a more favorable laparotomy incision or, potentially, to use a laparoscopic approach. We suggest <strong>not</strong> using GnRH agonist pretreatment for patients undergoing open or laparoscopic myomectomy. Use of these agents is a reasonable option in patients for whom treatment would allow a transverse rather than a vertical incision or a laparoscopic rather than open myomectomy and who place a high priority on type of surgical incision and/or duration of recovery.</p><p class="headingAnchor" id="H1388946"><span class="h1">INTRAOPERATIVE MEASURES</span><span class="headingEndMark"> — </span>Bleeding can be prevented or decreased with mechanical or pharmacologic methods. Unfortunately, none of these interventions has been proven to reduce the rate of blood transfusion. Allogeneic blood transfusion can be avoided by using methods of autologous blood transfusion.</p><p class="headingAnchor" id="H4413351"><span class="h2">Pharmacologic interventions</span><span class="headingEndMark"> — </span>Several pharmacologic agents reduce blood loss during myomectomy, although none has been proven to reduce the risk of blood transfusion. No studies have compared directly between these medications. Surgeons should use the agent with which they are most experienced, barring any individual patient contraindications. The most commonly used agent is <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a>.</p><p class="headingAnchor" id="H4413358"><span class="h3">Vasopressin and other vasoconstrictors</span><span class="headingEndMark"> — </span>Intramyometrial <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a> injected into the planned uterine incision site for each fibroid reduces blood loss. Vasopressin acts by constricting the smooth muscle in the walls of capillaries, small arterioles, and venules. Randomized trial data show that blood loss during myomectomy with vasopressin is significantly less than with placebo (299 mL less [<a href="#rid21">21</a>]) and less than or comparable to use of a uterine artery tourniquet [<a href="#rid22">22-24</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Safe use of </strong><a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a> – Vasopressin use during myomectomy has been associated with rare cases of bradycardia, cardiovascular collapse, and death [<a href="#rid24">24-28</a>]. Vasopressin use may be contraindicated in patients with medical comorbidities (eg, cardiovascular, vascular, or renal disease). The use of vasopressin to decrease blood loss during myomectomy has not been approved by the US Food and Drug Administration.</p><p></p><p class="bulletIndent1">Safe use of <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a> depends upon the surgeon's knowledge of its pharmacodynamics and use of safe practices. Care should be taken to avoid intravascular injection; before injecting, the surgeon should pull back on the plunger of the syringe to check for blood. However, complications may result even if intravascular injection does not occur. The maximal safe dose of vasopressin is not well established. Cardiovascular complications following intramyometrial injection have been reported in isolated cases with total vasopressin doses ranging from 5 to 11 units [<a href="#rid25">25-27,29,30</a>]. A classic prospective cohort study found no cardiovascular complication in 13 patients undergoing myomectomy who received a maximum of 4 units of intramyometrial vasopressin [<a href="#rid31">31</a>]. An upper limit of a cumulative total vasopressin dose per procedure of 4 to 6 units has been proposed [<a href="#rid32">32</a>]. Use of a dilute solution helps to limit the total dose. In our practice, we dilute 20 units of vasopressin in 100 mL of <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>; 4 to 6 units of vasopressin equals 20 to 30 mL of this solution. The half-life of intramuscular vasopressin is 10 to 20 minutes and the duration of action is two to eight hours.</p><p></p><p><a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">Epinephrine</a> is another vasoconstrictor that is effective in reducing blood loss during myomectomy. One randomized trial found that intramyometrial injection of <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> with epinephrine (50 mL bupivacaine hydrochloride 0.25 percent and 0.5 mL of 1 mg/mL epinephrine) reduced blood loss compared with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> (69 mL less) [<a href="#rid29">29</a>]. There were no differences in blood pressure or heart rate between groups. Intravascular injection of epinephrine may cause acute cardiovascular adverse events, similar to <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a>. A disadvantage of epinephrine is that clinical experience during myomectomy is limited, since most gynecologic surgeons use vasopressin in this setting.</p><p class="headingAnchor" id="H4413531"><span class="h3">Uterotonics</span><span class="headingEndMark"> — </span>Uterotonics have been used during myomectomy. One small randomized trial (n = 25) found that use of vaginal <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> (400 mcg, one hour before surgery) compared with placebo significantly reduced blood loss (149 mL less) [<a href="#rid33">33</a>]; further study of use of this agent during myomectomy is needed.</p><p>Data from a meta-analysis of two randomized trials including 77 patients showed that intravenous <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">oxytocin</a> does <strong>not</strong> reduce blood loss compared with physiologic serum (mean difference in blood loss -69 mL, 95% -297 to 157) [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H505640517"><span class="h3">Tranexamic acid</span><span class="headingEndMark"> — </span>In our practice, we administer <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> (10 mg/kg intravenously [IV] infused over 10 minutes) 20 minutes prior to surgical incision; larger doses have been described [<a href="#rid34">34</a>]. Tranexamic acid is contraindicated in patients with a history of thrombotic events [<a href="#rid35">35</a>].</p><p>However, randomized trials evaluating the efficacy of <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> on blood loss at time of myomectomy have yielded mixed results:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial including 100 patients undergoing open abdominal myomectomy, patients receiving <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> (10 mg/kg IV administered 15 minutes prior to incision) compared with placebo had a lower total blood loss (1047 [mean] versus 804 mL), but need for transfusion and postoperative hemoglobin were similar between groups [<a href="#rid36">36</a>]. Neither tourniquets nor other vasoconstrictive agents were used in either group. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial including 60 patients undergoing myomectomy (93 percent laparoscopic or robotic) for symptomatic fibroids and preoperative imaging demonstrating at least 1 fibroid ≥10 cm, any intramural or broad ligament fibroid ≥6 cm, and/or ≥5 total fibroids, those pretreated with <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> (15 mg/kg IV administered 20 minutes prior to incision) compared with placebo had similar total blood loss [<a href="#rid34">34</a>]. However, other methods to reduce blood loss during myomectomy (eg, tourniquets, vasoconstrictive agents) were used at the surgeon's discretion, and may have influenced results.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial including 80 patients undergoing open abdominal myomectomy, patients treated with <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> (10 mg/kg IV administered 10 to 15 minutes prior to incision) compared with placebo had similar intraoperative blood loss and rates of transfusion [<a href="#rid37">37</a>]; all patients also received an intraoperative tourniquet. However, when the estimated blood loss per 100 grams of fibroid removed was adjusted according to logarithm, patients receiving tranexamic acid compared with placebo had lower blood loss (104 versus 140 mL). </p><p></p><p>Use of <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> prior to gynecologic surgery for benign indications is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3302.html" rel="external">"Management of hemorrhage in gynecologic surgery", section on 'Prophylactic tranexamic acid'</a>.)</p><p class="headingAnchor" id="H4413538"><span class="h3">Other agents</span><span class="headingEndMark"> — </span>Sodium-2-mercaptoethanesulphonate (<a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">mesna</a>; used for chemical dissection) has been investigated but has not been found to be successful [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H1388953"><span class="h2">Tourniquets</span><span class="headingEndMark"> — </span>Use of tourniquets to occlude the uterine blood supply reduces blood loss during myomectomy. (See <a class="local">'Vascular anatomy of the uterus and leiomyomas'</a> above.)</p><p>The use of a tourniquet depends on the preoperative hemoglobin and the expected blood loss, usually related to the number of fibroids more than the size. A higher number of fibroids leads to more uterine incisions and more blood loss. There are no absolute criteria, but in our practice, we almost always use tourniquets to avoid as much blood loss as possible.</p><p>The benefit of use of a uterine artery tourniquet was illustrated in a randomized trial of 28 patients [<a href="#rid39">39</a>]. Use of a uterine artery tourniquet compared with no tourniquet resulted in a decrease in blood loss (an average of 1870 mL less).</p><p>Data conflict regarding whether tourniquet use is as effective as use of <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a>. Blood loss with use of a uterine artery tourniquet compared with intramyometrial vasopressin was lower in one randomized trial (an average of 225 mL less) [<a href="#rid23">23</a>] but was comparable in another trial [<a href="#rid22">22</a>]. There are no data regarding whether the combined use of a vasoconstrictor and tourniquets decreases blood loss more effectively than either measure alone. In our practice, we use vasopressin in addition to a tourniquet.</p><p>Procedures to apply a tourniquet vary. One technique is to place a catheter (eg, Robinson catheter, Penrose drain) around the lower uterine segment below the ovaries and fallopian tubes  (<a class="graphic graphic_figure graphicRef134401" href="/z/d/graphic/134401.html" rel="external">figure 2</a>); a latex-free tourniquet should be used in latex-allergic patients. Another method is to create bilateral small (ie, 1 cm) incisions in the broad ligament, just about the level of the internal os; the tourniquet is then passed through these incisions with the ends protruding anteriorly. Vascular clamps to the ovarian vessels may also be used  (<a class="graphic graphic_figure graphicRef71118" href="/z/d/graphic/71118.html" rel="external">figure 3</a>).</p><p>With either technique, care must be taken to avoid lacerating the ovarian vessels, compressing the ureter, and avoid injury to the distal portion of the fallopian tubes. The tourniquet is tightened and secured (with a Kelley clamp or tied) anteriorly. If lower segment fibroids are removed, the tourniquet may loosen and should be tightened again.</p><p>Use of number one suture as a uterine artery tourniquet during laparoscopic myomectomy has been reported [<a href="#rid39">39</a>]. In general, however, it is difficult to secure a tourniquet using laparoscopic instruments.</p><p>There are no high-quality data regarding the safe duration of tourniquet use to prevent uterine tissue damage. Some studies refer to releasing the tourniquet every 20 minutes, but outcomes for this practice have not been evaluated [<a href="#rid23">23,39</a>]. In addition, although the tourniquet may incorporate the ovarian vessels, studies evaluating anti-müllerian hormone levels before and after tourniquet placement suggest that the ovaries are resistant to hypoxia [<a href="#rid40">40,41</a>].</p><p class="headingAnchor" id="H1388988"><span class="h2">Autologous blood transfusion</span><span class="headingEndMark"> — </span>Autologous blood transfusion methods include autologous blood donation (rare), intraoperative or postoperative blood salvage, and acute normovolemic (isovolemic) hemodilution. </p><p>While there is no consensus regarding which method is most cost effective or acceptable to patients, perioperative autologous blood donation is rarely used. (See  <a class="medical medical_review" href="/z/d/html/7930.html" rel="external">"Surgical blood conservation: Preoperative autologous blood donation", section on 'Reasons for declining use'</a>.)</p><p class="headingAnchor" id="H6862472"><span class="h3">Intraoperative blood salvage</span><span class="headingEndMark"> — </span>In our practice, in procedures in which significant blood loss (≥300 mL) is anticipated, we have intraoperative blood salvage available. In a study of 91 patients who underwent open myomectomy for uterine size greater than 16 weeks, the operative blood loss ranged from 50 to 3000 mL [<a href="#rid3">3</a>]. The Cell Saver blood salvage was used for the 70 patients with a blood loss ≥300 mL; 7 patients received a homologous (non-autologous) blood transfusion in addition to blood salvage. The cost of using a cell-saver compared with donation of autologous blood has not been studied for abdominal myomectomy. Tourniquets were not used during this study, and since we implemented the routine use of tourniquets, we have rarely needed to use the cell-saver in our practice.</p><p class="headingAnchor" id="H2728258"><span class="h3">Normovolemic (isovolemic) hemodilution</span><span class="headingEndMark"> — </span>There is only one report of normovolemic (isovolemic) hemodilution during myomectomy [<a href="#rid42">42</a>], but we have not used this approach in our practice.</p><p>Methods of autologous transfusion and their use in gynecologic surgery are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7930.html" rel="external">"Surgical blood conservation: Preoperative autologous blood donation"</a> and  <a class="medical medical_review" href="/z/d/html/7937.html" rel="external">"Surgical blood conservation: Intraoperative blood salvage"</a> and  <a class="medical medical_review" href="/z/d/html/7936.html" rel="external">"Surgical blood conservation: Acute normovolemic hemodilution"</a> and  <a class="medical medical_review" href="/z/d/html/3302.html" rel="external">"Management of hemorrhage in gynecologic surgery", section on 'Autologous transfusion methods'</a>.)</p><p class="headingAnchor" id="H1388995"><span class="h2">Other measures</span><span class="headingEndMark"> — </span>Uterine artery ligation or embolization or internal iliac artery ligation may also be used to avoid hysterectomy when heavy bleeding is anticipated or occurs during myomectomy [<a href="#rid43">43,44</a>]. The uterine vessels will recannulate, so future fertility should theoretically be preserved. However, the impact on fertility and obstetric outcomes following uterine artery embolization as a primary procedure is not well established. For this reason, we reserve these techniques for situations in which other measures have failed and additional hemostasis is needed to avoid hysterectomy. (See  <a class="medical medical_review" href="/z/d/html/3302.html" rel="external">"Management of hemorrhage in gynecologic surgery", section on 'Internal iliac artery ligation'</a> and  <a class="medical medical_review" href="/z/d/html/3299.html" rel="external">"Uterine fibroids (leiomyomas): Treatment with uterine artery embolization"</a>.)</p><p class="headingAnchor" id="H3732327"><span class="h1">CLINICAL APPROACH</span><span class="headingEndMark"> — </span>There is no consensus about the optimal combination of preoperative or intraoperative measures to decrease blood loss or prepare for autologous blood transfusion. Few studies have compared among interventions. Also, most interventions have not been proven to reduce the risk of blood transfusion and/or avoid hysterectomy, the most important outcomes to patients.</p><p>Our approach is to employ basic methods for all procedures, and then use additional measures when significant blood loss (≥300 mL) is anticipated or occurs. Blood loss during myomectomy is correlated with the size and number of myomas, and also with operative duration, (which depends in large part upon the first two factors) [<a href="#rid22">22</a>]. During the preoperative evaluation of each patient, we assess the characteristics of the myomas and make our best clinical estimate of the risk of excessive blood loss. </p><p>In our practice, for all patients undergoing myomectomy, we do the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Correct preoperative anemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inject <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a> before each uterine incision.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many surgeons apply a uterine artery tourniquet (for open myomectomy only) in all patients. In our practice, we reserve the use of tourniquets for patients with large fibroids.</p><p></p><p>For patients in whom we anticipate significant blood loss (≥300 mL), we additionally do the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Prepare for the use of blood salvage.</p><p></p><p>Preoperative banking of autologous blood is also an option, but should be limited to patients in whom this will not result in anemia at the time of surgery.</p><p class="headingAnchor" id="H2957042760"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122885.html" rel="external">"Society guideline links: Gynecologic surgery"</a>.)</p><p class="headingAnchor" id="H1389289"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with leiomyomatous uteri have an increased number of uterine arterioles and venules and myomectomy may involve significant blood loss. The average volume of blood loss during abdominal myomectomy is 200 to 800 mL and for laparoscopic myomectomy is 80 to 250 mL. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest <strong>not</strong> using a gonadotropin-releasing hormone (GnRH) agonist pretreatment for patients undergoing abdominal or laparoscopic myomectomy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Use of these agents is a reasonable option in patients for whom treatment would allow a transverse rather than a vertical laparotomy or a laparoscopic rather than abdominal myomectomy and who place a high priority on type of surgical incision and/or duration of recovery. (See <a class="local">'GnRH agonists'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To reduce intraoperative blood loss for patients undergoing laparoscopic or abdominal myomectomy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We recommend intramyometrial injection of <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a> before each uterine incision (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Vasopressin and other vasoconstrictors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest placement of a tourniquet to occlude the uterine blood supply (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Tourniquets'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In our practice, we use <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> 20 minutes prior to surgical incision. (See <a class="local">'Tranexamic acid'</a> above.)</p><p></p><p class="bulletIndent2">The above measures may be used in combination, although it is uncertain whether combined use further decreases blood loss.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other agents that appear to reduce blood loss include <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> and <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>, but further study of these agents is needed. We recommend <strong>not</strong> using <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">oxytocin</a> for the purpose of reducing blood loss during myomectomy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Pharmacologic interventions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In our practice, in procedures in which significant blood loss (≥300 mL) occurs, we use intraoperative blood salvage. (See <a class="local">'Autologous blood transfusion'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sampson JA. The blood supply of uterine myomata. Surg Gynecol Obstet 1912; 14:215.</a></li><li><a class="nounderline abstract_t">Iverson RE Jr, Chelmow D, Strohbehn K, et al. Relative morbidity of abdominal hysterectomy and myomectomy for management of uterine leiomyomas. Obstet Gynecol 1996; 88:415.</a></li><li><a class="nounderline abstract_t">West S, Ruiz R, Parker WH. Abdominal myomectomy in women with very large uterine size. Fertil Steril 2006; 85:36.</a></li><li><a class="nounderline abstract_t">Sawin SW, Pilevsky ND, Berlin JA, Barnhart KT. Comparability of perioperative morbidity between abdominal myomectomy and hysterectomy for women with uterine leiomyomas. Am J Obstet Gynecol 2000; 183:1448.</a></li><li><a class="nounderline abstract_t">Paul GP, Naik SA, Madhu KN, Thomas T. Complications of laparoscopic myomectomy: A single surgeon's series of 1001 cases. Aust N Z J Obstet Gynaecol 2010; 50:385.</a></li><li><a class="nounderline abstract_t">Sinha R, Hegde A, Mahajan C, et al. Laparoscopic myomectomy: do size, number, and location of the myomas form limiting factors for laparoscopic myomectomy? J Minim Invasive Gynecol 2008; 15:292.</a></li><li class="breakAll">Falcone, T, Drake, et al. Surgical anatomy of the abdomen and pelvis. In: Clinical Reproductive Medicine and Surgery, Falcone, T, Hurd, WH (Eds), Mosby Elsevier, Philadelphia 2007. p.123.</li><li><a class="nounderline abstract_t">Discepola F, Valenti DA, Reinhold C, Tulandi T. Analysis of arterial blood vessels surrounding the myoma: relevance to myomectomy. Obstet Gynecol 2007; 110:1301.</a></li><li><a class="nounderline abstract_t">Walocha JA, Litwin JA, Miodoński AJ. Vascular system of intramural leiomyomata revealed by corrosion casting and scanning electron microscopy. Hum Reprod 2003; 18:1088.</a></li><li><a class="nounderline abstract_t">Shander A, Knight K, Thurer R, et al. Prevalence and outcomes of anemia in surgery: a systematic review of the literature. Am J Med 2004; 116 Suppl 7A:58S.</a></li><li><a class="nounderline abstract_t">Benoist S, Panis Y, Pannegeon V, et al. Predictive factors for perioperative blood transfusions in rectal resection for cancer: A multivariate analysis of a group of 212 patients. Surgery 2001; 129:433.</a></li><li><a class="nounderline abstract_t">Carson JL, Duff A, Poses RM, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet 1996; 348:1055.</a></li><li><a class="nounderline abstract_t">Muñoz M, Naveira E, Seara J, et al. Role of parenteral iron in transfusion requirements after total hip replacement. A pilot study. Transfus Med 2006; 16:137.</a></li><li><a class="nounderline abstract_t">Shander A, Spence RK, Auerbach M. Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents? Transfusion 2010; 50:719.</a></li><li><a class="nounderline abstract_t">Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev 2001; :CD000547.</a></li><li><a class="nounderline abstract_t">Muneyyirci-Delale O, Richard-Davis G, Morris T, Armstrong J. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial. Clin Ther 2007; 29:1682.</a></li><li><a class="nounderline abstract_t">Stovall TG, Muneyyirci-Delale O, Summitt RL Jr, Scialli AR. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group. Obstet Gynecol 1995; 86:65.</a></li><li><a class="nounderline abstract_t">Deligdisch L, Hirschmann S, Altchek A. Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata. Fertil Steril 1997; 67:837.</a></li><li><a class="nounderline abstract_t">Vercellini P, Trespìdi L, Zaina B, et al. Gonadotropin-releasing hormone agonist treatment before abdominal myomectomy: a controlled trial. Fertil Steril 2003; 79:1390.</a></li><li><a class="nounderline abstract_t">Campo S, Garcea N. Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotrophin-releasing hormone analogues. Hum Reprod 1999; 14:44.</a></li><li><a class="nounderline abstract_t">Kongnyuy EJ, Wiysonge CS. Interventions to reduce haemorrhage during myomectomy for fibroids. Cochrane Database Syst Rev 2011; :CD005355.</a></li><li><a class="nounderline abstract_t">Ginsburg ES, Benson CB, Garfield JM, et al. The effect of operative technique and uterine size on blood loss during myomectomy: a prospective randomized study. Fertil Steril 1993; 60:956.</a></li><li><a class="nounderline abstract_t">Fletcher H, Frederick J, Hardie M, Simeon D. A randomized comparison of vasopressin and tourniquet as hemostatic agents during myomectomy. Obstet Gynecol 1996; 87:1014.</a></li><li><a class="nounderline abstract_t">Zhao F, Jiao Y, Guo Z, et al. Evaluation of loop ligation of larger myoma pseudocapsule combined with vasopressin on laparoscopic myomectomy. Fertil Steril 2011; 95:762.</a></li><li><a class="nounderline abstract_t">Nezhat F, Admon D, Nezhat CH, et al. Life-threatening hypotension after vasopressin injection during operative laparoscopy, followed by uneventful repeat laparoscopy. J Am Assoc Gynecol Laparosc 1994; 2:83.</a></li><li><a class="nounderline abstract_t">Hobo R, Netsu S, Koyasu Y, Tsutsumi O. Bradycardia and cardiac arrest caused by intramyometrial injection of vasopressin during a laparoscopically assisted myomectomy. Obstet Gynecol 2009; 113:484.</a></li><li><a class="nounderline abstract_t">Tulandi T, Béique F, Kimia M. Pulmonary edema: a complication of local injection of vasopressin at laparoscopy. Fertil Steril 1996; 66:478.</a></li><li><a class="nounderline abstract_t">Lurie S, Mamet Y. Transient myocardial ischemia may occur following subendometrial vasopressin infiltration. Eur J Obstet Gynecol Reprod Biol 2000; 91:87.</a></li><li><a class="nounderline abstract_t">Zullo F, Palomba S, Corea D, et al. Bupivacaine plus epinephrine for laparoscopic myomectomy: a randomized placebo-controlled trial. Obstet Gynecol 2004; 104:243.</a></li><li><a class="nounderline abstract_t">Hung MH, Wang YM, Chia YY, et al. Intramyometrial injection of vasopressin causes bradycardia and cardiac arrest--report of two cases. Acta Anaesthesiol Taiwan 2006; 44:243.</a></li><li><a class="nounderline abstract_t">DILLON TF, MARBURY BE, BONSNES RW, et al. Vasopressin as a hemostatic in gynecologic surgery; a preliminary report. Obstet Gynecol 1958; 11:363.</a></li><li><a class="nounderline abstract_t">Frishman G. Vasopressin: if some is good, is more better? Obstet Gynecol 2009; 113:476.</a></li><li><a class="nounderline abstract_t">Celik H, Sapmaz E. Use of a single preoperative dose of misoprostol is efficacious for patients who undergo abdominal myomectomy. Fertil Steril 2003; 79:1207.</a></li><li><a class="nounderline abstract_t">Opoku-Anane J, Vargas MV, Marfori CQ, et al. Intraoperative tranexamic acid to decrease blood loss during myomectomy: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 2020; 223:413.e1.</a></li><li><a class="nounderline abstract_t">Bao J, Shore EM, Simpson AN, et al. Delphi Approach for the Design of an Intraoperative Blood Conservation Pathway for Open Myomectomy. J Obstet Gynaecol Can 2020; 42:31.</a></li><li><a class="nounderline abstract_t">Caglar GS, Tasci Y, Kayikcioglu F, Haberal A. Intravenous tranexamic acid use in myomectomy: a prospective randomized double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol 2008; 137:227.</a></li><li><a class="nounderline abstract_t">Abdul IF, Amadu MB, Adesina KT, et al. Adjunctive use of tranexamic acid to tourniquet in reducing haemorrhage during abdominal myomectomy - A randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 2019; 242:150.</a></li><li><a class="nounderline abstract_t">Benassi L, Lopopolo G, Pazzoni F, et al. Chemically assisted dissection of tissues: an interesting support in abdominal myomectomy. J Am Coll Surg 2000; 191:65.</a></li><li><a class="nounderline abstract_t">Taylor A, Sharma M, Tsirkas P, et al. Reducing blood loss at open myomectomy using triple tourniquets: a randomised controlled trial. BJOG 2005; 112:340.</a></li><li><a class="nounderline abstract_t">Al RA, Yapca OE, Gumusburun N. A Randomized Trial Comparing Triple versus Single Uterine Tourniquet in Open Myomectomy. Gynecol Obstet Invest 2017; 82:547.</a></li><li><a class="nounderline abstract_t">Aharon D, Sekhon L, Getrajdman C, et al. Association of Myomectomy With Anti-Müllerian Hormone Levels and Ovarian Reserve. Obstet Gynecol 2022; 140:1000.</a></li><li><a class="nounderline abstract_t">Nussbaum W, deCastro N, Campbell FW. Perioperative challenges in the care of the Jehovah's Witness: a case report. AANA J 1994; 62:160.</a></li><li><a class="nounderline abstract_t">Helal AS, Abdel-Hady el-S, Refaie E, et al. Preliminary uterine artery ligation versus pericervical mechanical tourniquet in reducing hemorrhage during abdominal myomectomy. Int J Gynaecol Obstet 2010; 108:233.</a></li><li><a class="nounderline abstract_t">Dumousset E, Chabrot P, Rabischong B, et al. Preoperative uterine artery embolization (PUAE) before uterine fibroid myomectomy. Cardiovasc Intervent Radiol 2008; 31:514.</a></li></ol></div><div id="topicVersionRevision">Topic 15798 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The blood supply of uterine myomata</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8752251" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Relative morbidity of abdominal hysterectomy and myomectomy for management of uterine leiomyomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16412723" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Abdominal myomectomy in women with very large uterine size.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11120509" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparability of perioperative morbidity between abdominal myomectomy and hysterectomy for women with uterine leiomyomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20716269" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Complications of laparoscopic myomectomy: A single surgeon's series of 1001 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18439500" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Laparoscopic myomectomy: do size, number, and location of the myomas form limiting factors for laparoscopic myomectomy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18439500" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Laparoscopic myomectomy: do size, number, and location of the myomas form limiting factors for laparoscopic myomectomy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18055724" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Analysis of arterial blood vessels surrounding the myoma: relevance to myomectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12721189" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Vascular system of intramural leiomyomata revealed by corrosion casting and scanning electron microscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15050887" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevalence and outcomes of anemia in surgery: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11283534" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Predictive factors for perioperative blood transfusions in rectal resection for cancer: A multivariate analysis of a group of 212 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8874456" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of anaemia and cardiovascular disease on surgical mortality and morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16623920" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Role of parenteral iron in transfusion requirements after total hip replacement. A pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19919555" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11405968" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919549" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7784025" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9130887" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12798887" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Gonadotropin-releasing hormone agonist treatment before abdominal myomectomy: a controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10374092" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotrophin-releasing hormone analogues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22071823" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Interventions to reduce haemorrhage during myomectomy for fibroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8243699" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The effect of operative technique and uterine size on blood loss during myomectomy: a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8649682" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A randomized comparison of vasopressin and tourniquet as hemostatic agents during myomectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20883988" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Evaluation of loop ligation of larger myoma pseudocapsule combined with vasopressin on laparoscopic myomectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9050538" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Life-threatening hypotension after vasopressin injection during operative laparoscopy, followed by uneventful repeat laparoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155928" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bradycardia and cardiac arrest caused by intramyometrial injection of vasopressin during a laparoscopically assisted myomectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8751752" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pulmonary edema: a complication of local injection of vasopressin at laparoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10817886" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Transient myocardial ischemia may occur following subendometrial vasopressin infiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15291994" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Bupivacaine plus epinephrine for laparoscopic myomectomy: a randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17233372" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Intramyometrial injection of vasopressin causes bradycardia and cardiac arrest--report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13517741" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Vasopressin as a hemostatic in gynecologic surgery; a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155925" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Vasopressin: if some is good, is more better?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738519" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Use of a single preoperative dose of misoprostol is efficacious for patients who undergo abdominal myomectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32229194" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Intraoperative tranexamic acid to decrease blood loss during myomectomy: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31296447" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Delphi Approach for the Design of an Intraoperative Blood Conservation Pathway for Open Myomectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17499419" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Intravenous tranexamic acid use in myomectomy: a prospective randomized double-blind placebo controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31600715" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Adjunctive use of tranexamic acid to tourniquet in reducing haemorrhage during abdominal myomectomy - A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10898185" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Chemically assisted dissection of tissues: an interesting support in abdominal myomectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15713151" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Reducing blood loss at open myomectomy using triple tourniquets: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28380474" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A Randomized Trial Comparing Triple versus Single Uterine Tourniquet in Open Myomectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36441930" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Association of Myomectomy With Anti-Müllerian Hormone Levels and Ovarian Reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8085419" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Perioperative challenges in the care of the Jehovah's Witness: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19945103" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Preliminary uterine artery ligation versus pericervical mechanical tourniquet in reducing hemorrhage during abdominal myomectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17624572" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Preoperative uterine artery embolization (PUAE) before uterine fibroid myomectomy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
